tiprankstipranks
Crinetics Pharmaceuticals (CRNX)
NASDAQ:CRNX
US Market

Crinetics Pharmaceuticals (CRNX) Ownership - Who Owns Crinetics Pharmaceuticals?

428 Followers

Crinetics Pharmaceuticals (CRNX) Ownership Overview

9.61%26.49%11.94%51.95%
11.94% Other Institutional Investors
51.95% Public Companies and
Individual Investors
The ownership structure of Crinetics Pharmaceuticals (CRNX) stock is a mix of institutional, retail and individual investors. Approximately 38.44% of the company’s stock is owned by Institutional Investors, 9.61% is owned by Insiders and 51.95% is owned by Public Companies and Individual Investors.
The ownership structure of Crinetics Pharmaceuticals (CRNX) stock is a mix of institutional, retail and individual investors. Approximately 38.44% of the company’s stock is owned by Institutional Investors, 9.61% is owned by Insiders and 51.95% is owned by Public Companies and Individual Investors.

Recent Insider Trading Activity

Date
Name
Activity
Value
Jun 25, 2024
Dana Pizzuti
Chief Med And Dev Officer
Sold$434435
Apr 02, 2024Sold$811650
Mar 26, 2024Sold$1433675
Mar 22, 2024
Dana Pizzuti
Chief Med And Dev Officer
Sold$664763

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Mar 31, 2024Sold$234050
Mar 31, 2024Bought$7180419
Mar 31, 2024Bought$14464290
Mar 31, 2024Sold$20410236

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
5,226,297Institution6.63%240,775,503
3,454,861Institution4.38%159,165,446
3,417,967Institution4.33%157,465,740
2,843,853Institution3.61%131,016,308
1,499,632Institution1.90%69,088,046
1,476,203Institution1.87%68,008,672
1,415,450Institution1.79%65,209,782
1,413,650Institution1.79%65,126,856
1,238,921Institution1.57%57,077,090
1,141,633Institution1.45%52,595,032

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
2,843,853Institution3.61%131,016,308
1,499,632Institution1.90%69,088,046
1,415,450Institution1.79%65,209,782
1,413,650Institution1.79%65,126,856
1,141,633Institution1.45%52,595,032
880,332Institution1.12%40,556,895
827,692Institution1.05%38,131,770
716,630Institution0.91%33,015,144
709,769Institution0.90%32,699,058
674,789Institution0.86%31,087,529

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,998,367Institution2.53%88,747,478
1,890,691Institution2.40%87,104,134
1,160,568Institution1.47%51,981,841
875,285Institution1.11%38,871,407
686,944Institution0.87%31,647,510
545,438Institution0.69%25,128,329
321,054Institution0.41%14,380,009
247,228Institution0.31%10,979,395
223,156Institution0.28%9,910,358
131,315Institution0.17%6,049,682

FAQ

Who Owns Crinetics Pharmaceuticals (CRNX)?
According to the latest TipRanks data, approximately 11.94% of the company's stock is held by institutional investors, 9.61% is held by insiders, and 51.95% is held by retail investors.
    What percentage of Crinetics Pharmaceuticals (CRNX) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 11.94% of Crinetics Pharmaceuticals (CRNX) stock is held by institutional investors.
      What percentage of Crinetics Pharmaceuticals (CRNX) stock is held by retail investors?
      According to the latest TipRanks data, approximately 51.95% of Crinetics Pharmaceuticals (CRNX) stock is held by retail investors.
        Who owns the most shares of Crinetics Pharmaceuticals (CRNX)?
        Richard Driehaus owns the most shares of Crinetics Pharmaceuticals (CRNX).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What's Included in PREMIUM?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis